Foundation Medicine Given Consensus Recommendation of “Hold” by Analysts (NYSE:FMI)
Shares of Foundation Medicine (NYSE:FMI) have been given a consensus rating of “Hold” by the nine ratings firms that are presently covering the stock, StockRatingsNetwork reports. Six research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $38.80.
Shares of Foundation Medicine (NYSE:FMI) traded down 0.04% during mid-day trading on Thursday, hitting $24.04. The stock had a trading volume of 5,029 shares. Foundation Medicine has a 52-week low of $19.513 and a 52-week high of $45.00. The stock has a 50-day moving average of $25.56 and a 200-day moving average of $28.46. The company’s market cap is $677.7 million.
Several analysts have recently commented on the stock. Analysts at Tigress Financial initiated coverage on shares of Foundation Medicine in a research note on Friday, August 1st. They set a “neutral” rating on the stock. Separately, analysts at Janney Montgomery Scott initiated coverage on shares of Foundation Medicine in a research note on Wednesday, June 25th. They set a “neutral” rating and a $28.00 price target on the stock. Finally, analysts at Leerink Swann cut their price target on shares of Foundation Medicine from $36.00 to $33.00 in a research note on Friday, May 9th.
Foundation Medicine, Inc is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.